TREM1 activation of myeloid cells promotes antitumor immunity
Science Translational Medicine · 2023
DOI: 10.1126/scitranslmed.add9990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Vladislava Juric und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pionyr Immunotherapeutics, 2 Tower Place, Suite 800, South San Francisco, CA 94080, USA. Hauptthemen laut MEDLINE: Monocytes, Myeloid Cells. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Myeloid cells in the tumor microenvironment (TME) can exist in immunosuppressive and immunostimulatory states that impede or promote antitumor immunity, respectively. Blocking suppressive myeloid cells or increasing stimulatory cells to enhance antitumor immune responses is an area of interest for therapeutic intervention. Triggering receptor expressed on myeloid cells-1 (TREM1) is a proinflammatory receptor that amplifies immune responses. TREM1 is expressed on neutrophils, subsets of monocytes and tissue macrophages, and suppressive myeloid populations in the TME, including tumor-associated neutrophils, monocytes, and tumor-associated macrophages. Depletion or inhibition of immunosuppressive myeloid cells, or stimulation by TREM1-mediated inflammatory signaling, could be used to promote an immunostimulatory TME. We developed PY159, an afucosylated humanized anti-TREM1 monoclonal antibody with enhanced FcγR binding. PY159 is a TREM1 agonist that induces signaling, leading to up-regulation of costimulatory molecules on monocytes and macrophages, production of proinflammatory cytokines and chemokines, and enhancement of T cell activation in vitro. An antibody against mouse TREM1, PY159m, promoted antitumor efficacy in syngeneic mouse tumor models. These results suggest that PY159-mediated agonism of TREM1 on tumoral myeloid cells can promote a proinflammatory TME and offer a promising strategy for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pionyr Immunotherapeutics, 2 Tower Place, Suite 800, South San Francisco, CA 94080, USA.
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
ORCID-Profile: Vladislava Juric, Joshua Rudolph, Chris Brassell, Erick Lu, Venkataraman Sriram, Michel Streuli, Matthew F Krummel, Kevin P Baker, Linda Liang
Zitieren
APA
Juric, V., Mayes, E., Binnewies, M., Lee, T., Canaday, P., Pollack, J. L., Rudolph, J., Du, X., Liu, V. M., Dash, S., Palmer, R., Jahchan, N. S., Ramoth, Å. J., Lacayo, S., Mankikar, S., Norng, M., Brassell, C., Pal, A., Chan, C., …, & Liang, L. (2023). TREM1 activation of myeloid cells promotes antitumor immunity. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.add9990
Vancouver
Juric V, Mayes E, Binnewies M, Lee T, Canaday P, Pollack JL, et al. TREM1 activation of myeloid cells promotes antitumor immunity. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.add9990
BibTeX
@article{Juric2023,
author = {Juric, Vladislava and Mayes, Erin and Binnewies, Mikhail and Lee, Tian and Canaday, Pamela and Pollack, Joshua L and Rudolph, Joshua and Du, Xiaoyan and Liu, Victoria M and Dash, Subhadra and Palmer, Rachael and Jahchan, Nadine S and Ramoth, Åsa Johanna and Lacayo, Sergio and Mankikar, Shilpa and Norng, Manith and Brassell, Chris and Pal, Aritra and Chan, Christopher and Lu, Erick and Sriram, Venkataraman and Streuli, Michel and Krummel, Matthew F and Baker, Kevin P and Liang, Linda},
title = {TREM1 activation of myeloid cells promotes antitumor immunity},
journal = {Science Translational Medicine},
year = {2023},
doi = {10.1126/scitranslmed.add9990}
}
EUVIMED